全体要約
遺伝性肥満治療薬市場は、2022年の売上高を基に、2023年から2029年にかけての成長が見込まれています。特に、米国、中国、欧州の市場はそれぞれの地域での成長が期待されており、主要企業にはファイザー、サノフィ、ノボノルディスクなどが含まれます。市場は、シブトラミンやオルリスタットなどの製品タイプや、病院薬局、小売薬局、オンライン薬局などのアプリケーションによってセグメント化されています。
この市場は、遺伝性肥満治療薬の需要が高まる中で、食欲抑制ホルモンの回復に関する進展が影響を与えています。2022年の売上高は数百万米ドルに達し、2029年までの成長率はCAGRで示されています。市場の成長機会や主要なトレンドが分析され、地域別の詳細なデータが提供されています。
関連する質問
Pfizer, Inc., Sanofi., Tonghua Dongbao Pharmaceutical Co., Ltd., Biocon., Adocia, GlaxoSmithKline Plc., Novo Nordisk A/S., Oramed Pharmaceuticals, Inc., Wockhardt., Eli Lilly and Company., Merck & Co., Inc., Julphar., Bristol-Myers Squibb Company.
食欲抑制ホルモンレベルの回復, 遺伝性肥満治療薬の採用増加, 市場セグメンテーションの分析
概要
LPI (LP Information)の最新の研究報告書「遺伝性肥満治療薬業界予測」は、過去の販売を調査し、2022年の世界の遺伝性肥満治療薬の総販売額をレビューしています。この報告書は、2023年から2029年にかけての遺伝性肥満治療薬の予測販売について、地域および市場セクターごとの包括的な分析を提供します。遺伝性肥満治療薬の販売は地域、市場セクターおよびサブセクターごとに分解されており、この報告書は世界の遺伝性肥満治療薬産業の詳細な分析を百万米ドル単位で提供。
このインサイトレポートは、世界の遺伝性肥満薬の市場を包括的に分析し、製品セグメンテーション、企業形成、収益、市場シェア、最新の動向、M&A活動に関連する主要なトレンドを強調しています。また、このレポートは、遺伝性肥満薬のポートフォリオと能力、市場参入戦略、市場ポジション、地理的な存在感に焦点を当て、世界の遺伝性肥満薬市場の加速する中でこれらの企業の独自の立ち位置をよりよく理解するために、主要なグローバル企業の戦略を分析しています。
このインサイトレポートは、遺伝的肥満薬に関する主要な市場トレンド、ドライバー、および影響要因を評価し、タイプ、アプリケーション、地理、そして市場規模によって予測を分解し、新たな機会のポケットを浮き彫りにします。数百のボトムアップの質的および量的市場データに基づく透明な方法論を用いたこの研究予測は、遺伝的肥満薬の現在の状態と未来の軌道について非常にニュアンスのある見方を提供します。
世界の遺伝的肥満治療薬市場の規模は、2022年のXX米ドルから2029年のXX米ドルに成長すると予測されています。2023年から2029年の間に、CAGRはXX%の成長が期待されています。
アメリカの遺伝的肥満薬市場は、2022年のXX米ドルから2029年にはXX米ドルに増加すると推定されており、2023年から2029年までの間にXX%の年平均成長率（CAGR）を示す見込みです。
中国の遺伝性肥満薬市場は、2022年のUS$ミリオンから2029年までにUS$ミリオンに増加することが見込まれており、2023年から2029年の間にXX%の年平均成長率（CAGR）を達成する見込みです。
2022年から2029年までの間に、遺伝子肥満薬のヨーロッパ市場は、XX米ドルからXX米ドルへと増加し、2023年から2029年の間でXX%のCAGRを記録すると推定されています。
グローバルな主要遺伝子肥満薬のプレーヤーには、ファイザー、サノフィ、通化東宝製薬、バイオコン、アドシア、グラクソ・スミスクライン、ノボノルディスク、オラメド・ファーマシューティカルズ、ウォカートなどが含まれます。収益の観点では、2022年において、世界の二大企業がほぼXX%のシェアを占めていました。
このレポートは、製品タイプ、アプリケーション、主要プレイヤー、主要地域および国別の遺伝性肥満薬市場の包括的な概要、市場シェア、および成長機会を提示しています。
市場セグメンテーション
タイプ別セグメンテーション
シブトラミン
オルリスタット
交感神経興奮薬
受容体拮抗薬
その他
アプリケーション別のセグメンテーション
病院の薬局
小売薬局
オンライン薬局
その他
この報告書では、市場を地域別に分割しています。
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中東およびアフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、プライマリ専門家からの意見と企業のカバレッジ、製品ポートフォリオ、市場浸透率を分析した結果に基づいて選定されています。
ファイザー社
サノフィ
通化東宝薬業有限公司
バイオコン
アドシア
グラクソ・スミスクライン株式会社
ノボ ノルディスク A/S
オラメド・ファーマシューティカルト株式会社
ワッカート
イーライリリー社
メルク・アンド・カンパニー・インク
ジュルファー
ブリストル・マイヤーズ スクイブ社。
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルの遺伝性肥満治療薬市場規模、（2018年～2029年）
2.1.2 遺伝性肥満治療薬市場規模、CAGR（地域別）（2018年 vs 2022年 vs 2029年）
2.2 遺伝性肥満治療薬セグメント、タイプ別
2.2.1 シブトラミン
2.2.2 オルリスタット
2.2.3 交感神経刺激薬
2.2.4 受容体アンタゴニスト
2.2.5 その他
2.3 遺伝性肥満治療薬市場規模：タイプ別
2.3.1 遺伝性肥満治療薬市場規模、CAGR（タイプ別）（2018年 vs 2022年 vs 2029年）
2.3.2 グローバルの遺伝性肥満治療薬市場規模、市場シェア（タイプ別）（2018年～2023年）
2.4 遺伝性肥満治療薬セグメント、用途別
2.4.1 病院薬局
2.4.2 小売薬局
2.4.3 オンラインファーマシー
2.4.4 その他
2.5 遺伝性肥満治療薬市場規模：用途別
2.5.1 遺伝性肥満治療薬市場規模、CAGR（用途別）（2018年 vs 2022年 vs 2029年）
2.5.2 グローバルの遺伝性肥満治療薬市場規模、市場シェア（用途別）（2018年～2023年）
3 遺伝性肥満治療薬市場規模：プレイヤー別
3.1 遺伝性肥満治療薬市場規模、市場シェア（プレイヤー別）
3.1.1 グローバルにおける遺伝性肥満治療薬市場の収益規模、プレイヤー別（2018年～2023年）
3.1.2 グローバルにおける遺伝性肥満治療薬市場の収益シェア、プレイヤー別（2018年～2023年）
3.2 グローバルの遺伝性肥満治療薬市場キープレイヤー拠点および提供製品
3.3 市場集中度分析
3.3.1 競合情勢分析
3.3.2 集中度レシオ（CR3、CR5、CR10）（2021年～2023年）
3.4 新製品・潜在的参入
3.5 M&A、拡大
4 遺伝性肥満治療薬、地域別
4.1 遺伝性肥満治療薬市場規模（地域別）（2018年～2023年）
4.2 アメリカズにおける遺伝性肥満治療薬市場規模成長（2018年〜2023年）
4.3 APACにおける遺伝性肥満治療薬市場規模成長（2018年〜2023年）
4.4 ヨーロッパにおける遺伝性肥満治療薬市場規模成長（2018年〜2023年）
4.5 中東・アフリカにおける遺伝性肥満治療薬市場規模成長（2018年〜2023年）
5 アメリカズ
5.1 アメリカズにおける遺伝性肥満治療薬市場規模、国別（2018年〜2023年）
5.2 アメリカズにおける遺伝性肥満治療薬市場規模、タイプ別（2018年〜2023年）
5.3 アメリカズにおける遺伝性肥満治療薬市場規模、用途別（2018年〜2023年）
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおける遺伝性肥満治療薬市場規模、地域別（2018年〜2023年）
6.2 APACにおける遺伝性肥満治療薬市場規模、タイプ別（2018年〜2023年）
6.3 APACにおける遺伝性肥満治療薬市場規模、用途別（2018年〜2023年）
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
7 ヨーロッパ
7.1 ヨーロッパの遺伝性肥満治療薬 国別（2018年～2023年）
7.2 ヨーロッパにおける遺伝性肥満治療薬市場規模、タイプ別（2018年〜2023年）
7.3 ヨーロッパにおける遺伝性肥満治療薬市場規模、用途別（2018年〜2023年）
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカの遺伝性肥満治療薬 地域別（2018年～2023年）
8.2 中東・アフリカにおける遺伝性肥満治療薬市場規模、タイプ別（2018年〜2023年）
8.3 中東・アフリカにおける遺伝性肥満治療薬市場規模、用途別（2018年〜2023年）
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 グローバルの遺伝性肥満治療薬市場、市場予測
10.1 グローバルの遺伝性肥満治療薬、市場予測（地域別）（2024年～2029年）
10.1.1 グローバルの遺伝性肥満治療薬、市場予測（地域別）（2024年～2029年）
10.1.2 アメリカズの遺伝性肥満治療薬、市場予測
10.1.3 APACの遺伝性肥満治療薬、市場予測
10.1.4 ヨーロッパの遺伝性肥満治療薬、市場予測
10.1.5 中東・アフリカの遺伝性肥満治療薬、市場予測
10.2 アメリカズの遺伝性肥満治療薬、市場予測（国別）（2024年～2029年）
10.3 APACの遺伝性肥満治療薬、市場予測（地域別）（2024年～2029年）
10.4 ヨーロッパの遺伝性肥満治療薬、市場予測（国別）（2024年～2029年）
10.5 中東・アフリカの遺伝性肥満治療薬、市場予測（地域別）（2024年～2029年）
10.6 グローバルの遺伝性肥満治療薬、市場予測（タイプ別）（2024年～2029年）
10.7 グローバルの遺伝性肥満治療薬、市場予測（用途別）（2024年～2029年）
11 キープレイヤー分析
11.1 Pfizer, Inc
11.2 Sanofi
11.3 Tonghua Dongbao Pharmaceutical Co\., Ltd
11.4 Biocon
11.5 Adocia
11.5.1 Adocia：企業情報
11.5.2 Adocia：遺伝性肥満治療薬分野の提供製品
11.5.3 Adocia：遺伝性肥満治療薬収益・グロスマージンおよび市場シェア（2018年～2023年）
11.5.4 Adocia：主要事業概要
11.5.5 Adocia：直近の展開
11.6 GlaxoSmithKline Plc
11.7 Novo Nordisk A/S
11.8 Oramed Pharmaceuticals, Inc
11.8.1 Oramed Pharmaceuticals, Inc：企業情報
11.8.2 Oramed Pharmaceuticals, Inc：遺伝性肥満治療薬分野の提供製品
11.8.3 Oramed Pharmaceuticals, Inc：遺伝性肥満治療薬収益・グロスマージンおよび市場シェア（2018年～2023年）
11.8.4 Oramed Pharmaceuticals, Inc：主要事業概要
11.8.5 Oramed Pharmaceuticals, Inc：直近の展開
11.9 Wockhardt
11.10 Eli Lilly and Company
11.11 Merck & Co\., Inc
11.12 Julphar
11.13 Bristol-Myers Squibb Company
12 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
LPI (LP Information)' newest research report, the “Genetic Obesity Drug Industry Forecast” looks at past sales and reviews total world Genetic Obesity Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Genetic Obesity Drug sales for 2023 through 2029. With Genetic Obesity Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genetic Obesity Drug industry.
This Insight Report provides a comprehensive analysis of the global Genetic Obesity Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Genetic Obesity Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Genetic Obesity Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genetic Obesity Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genetic Obesity Drug.
The global Genetic Obesity Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Genetic Obesity Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Genetic Obesity Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Genetic Obesity Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Genetic Obesity Drug players cover Pfizer, Inc., Sanofi., Tonghua Dongbao Pharmaceutical Co., Ltd., Biocon., Adocia, GlaxoSmithKline Plc., Novo Nordisk A/S., Oramed Pharmaceuticals, Inc and Wockhardt., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Genetic Obesity Drug market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Sibutramine
Orlistat
Sympathomimetic Drugs
Receptors Antagonists
Others
Segmentation by application
Hospitals Pharmacy
Retail Pharmacy
Online Pharmacy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer, Inc.
Sanofi.
Tonghua Dongbao Pharmaceutical Co., Ltd.
Biocon.
Adocia
GlaxoSmithKline Plc.
Novo Nordisk A/S.
Oramed Pharmaceuticals, Inc
Wockhardt.
Eli Lilly and Company.
Merck & Co., Inc.
Julphar.
Bristol-Myers Squibb Company.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Genetic Obesity Drug Market Size 2018-2029
2.1.2 Genetic Obesity Drug Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Genetic Obesity Drug Segment by Type
2.2.1 Sibutramine
2.2.2 Orlistat
2.2.3 Sympathomimetic Drugs
2.2.4 Receptors Antagonists
2.2.5 Others
2.3 Genetic Obesity Drug Market Size by Type
2.3.1 Genetic Obesity Drug Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Genetic Obesity Drug Market Size Market Share by Type (2018-2023)
2.4 Genetic Obesity Drug Segment by Application
2.4.1 Hospitals Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.4.4 Others
2.5 Genetic Obesity Drug Market Size by Application
2.5.1 Genetic Obesity Drug Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Genetic Obesity Drug Market Size Market Share by Application (2018-2023)
3 Genetic Obesity Drug Market Size by Player
3.1 Genetic Obesity Drug Market Size Market Share by Players
3.1.1 Global Genetic Obesity Drug Revenue by Players (2018-2023)
3.1.2 Global Genetic Obesity Drug Revenue Market Share by Players (2018-2023)
3.2 Global Genetic Obesity Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Genetic Obesity Drug by Regions
4.1 Genetic Obesity Drug Market Size by Regions (2018-2023)
4.2 Americas Genetic Obesity Drug Market Size Growth (2018-2023)
4.3 APAC Genetic Obesity Drug Market Size Growth (2018-2023)
4.4 Europe Genetic Obesity Drug Market Size Growth (2018-2023)
4.5 Middle East & Africa Genetic Obesity Drug Market Size Growth (2018-2023)
5 Americas
5.1 Americas Genetic Obesity Drug Market Size by Country (2018-2023)
5.2 Americas Genetic Obesity Drug Market Size by Type (2018-2023)
5.3 Americas Genetic Obesity Drug Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Genetic Obesity Drug Market Size by Region (2018-2023)
6.2 APAC Genetic Obesity Drug Market Size by Type (2018-2023)
6.3 APAC Genetic Obesity Drug Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Genetic Obesity Drug by Country (2018-2023)
7.2 Europe Genetic Obesity Drug Market Size by Type (2018-2023)
7.3 Europe Genetic Obesity Drug Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Genetic Obesity Drug by Region (2018-2023)
8.2 Middle East & Africa Genetic Obesity Drug Market Size by Type (2018-2023)
8.3 Middle East & Africa Genetic Obesity Drug Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Genetic Obesity Drug Market Forecast
10.1 Global Genetic Obesity Drug Forecast by Regions (2024-2029)
10.1.1 Global Genetic Obesity Drug Forecast by Regions (2024-2029)
10.1.2 Americas Genetic Obesity Drug Forecast
10.1.3 APAC Genetic Obesity Drug Forecast
10.1.4 Europe Genetic Obesity Drug Forecast
10.1.5 Middle East & Africa Genetic Obesity Drug Forecast
10.2 Americas Genetic Obesity Drug Forecast by Country (2024-2029)
10.2.1 United States Genetic Obesity Drug Market Forecast
10.2.2 Canada Genetic Obesity Drug Market Forecast
10.2.3 Mexico Genetic Obesity Drug Market Forecast
10.2.4 Brazil Genetic Obesity Drug Market Forecast
10.3 APAC Genetic Obesity Drug Forecast by Region (2024-2029)
10.3.1 China Genetic Obesity Drug Market Forecast
10.3.2 Japan Genetic Obesity Drug Market Forecast
10.3.3 Korea Genetic Obesity Drug Market Forecast
10.3.4 Southeast Asia Genetic Obesity Drug Market Forecast
10.3.5 India Genetic Obesity Drug Market Forecast
10.3.6 Australia Genetic Obesity Drug Market Forecast
10.4 Europe Genetic Obesity Drug Forecast by Country (2024-2029)
10.4.1 Germany Genetic Obesity Drug Market Forecast
10.4.2 France Genetic Obesity Drug Market Forecast
10.4.3 UK Genetic Obesity Drug Market Forecast
10.4.4 Italy Genetic Obesity Drug Market Forecast
10.4.5 Russia Genetic Obesity Drug Market Forecast
10.5 Middle East & Africa Genetic Obesity Drug Forecast by Region (2024-2029)
10.5.1 Egypt Genetic Obesity Drug Market Forecast
10.5.2 South Africa Genetic Obesity Drug Market Forecast
10.5.3 Israel Genetic Obesity Drug Market Forecast
10.5.4 Turkey Genetic Obesity Drug Market Forecast
10.5.5 GCC Countries Genetic Obesity Drug Market Forecast
10.6 Global Genetic Obesity Drug Forecast by Type (2024-2029)
10.7 Global Genetic Obesity Drug Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Pfizer, Inc.
11.1.1 Pfizer, Inc. Company Information
11.1.2 Pfizer, Inc. Genetic Obesity Drug Product Offered
11.1.3 Pfizer, Inc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Pfizer, Inc. Main Business Overview
11.1.5 Pfizer, Inc. Latest Developments
11.2 Sanofi.
11.2.1 Sanofi. Company Information
11.2.2 Sanofi. Genetic Obesity Drug Product Offered
11.2.3 Sanofi. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Sanofi. Main Business Overview
11.2.5 Sanofi. Latest Developments
11.3 Tonghua Dongbao Pharmaceutical Co., Ltd.
11.3.1 Tonghua Dongbao Pharmaceutical Co., Ltd. Company Information
11.3.2 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Product Offered
11.3.3 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Tonghua Dongbao Pharmaceutical Co., Ltd. Main Business Overview
11.3.5 Tonghua Dongbao Pharmaceutical Co., Ltd. Latest Developments
11.4 Biocon.
11.4.1 Biocon. Company Information
11.4.2 Biocon. Genetic Obesity Drug Product Offered
11.4.3 Biocon. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Biocon. Main Business Overview
11.4.5 Biocon. Latest Developments
11.5 Adocia
11.5.1 Adocia Company Information
11.5.2 Adocia Genetic Obesity Drug Product Offered
11.5.3 Adocia Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Adocia Main Business Overview
11.5.5 Adocia Latest Developments
11.6 GlaxoSmithKline Plc.
11.6.1 GlaxoSmithKline Plc. Company Information
11.6.2 GlaxoSmithKline Plc. Genetic Obesity Drug Product Offered
11.6.3 GlaxoSmithKline Plc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 GlaxoSmithKline Plc. Main Business Overview
11.6.5 GlaxoSmithKline Plc. Latest Developments
11.7 Novo Nordisk A/S.
11.7.1 Novo Nordisk A/S. Company Information
11.7.2 Novo Nordisk A/S. Genetic Obesity Drug Product Offered
11.7.3 Novo Nordisk A/S. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Novo Nordisk A/S. Main Business Overview
11.7.5 Novo Nordisk A/S. Latest Developments
11.8 Oramed Pharmaceuticals, Inc
11.8.1 Oramed Pharmaceuticals, Inc Company Information
11.8.2 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Product Offered
11.8.3 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Oramed Pharmaceuticals, Inc Main Business Overview
11.8.5 Oramed Pharmaceuticals, Inc Latest Developments
11.9 Wockhardt.
11.9.1 Wockhardt. Company Information
11.9.2 Wockhardt. Genetic Obesity Drug Product Offered
11.9.3 Wockhardt. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Wockhardt. Main Business Overview
11.9.5 Wockhardt. Latest Developments
11.10 Eli Lilly and Company.
11.10.1 Eli Lilly and Company. Company Information
11.10.2 Eli Lilly and Company. Genetic Obesity Drug Product Offered
11.10.3 Eli Lilly and Company. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Eli Lilly and Company. Main Business Overview
11.10.5 Eli Lilly and Company. Latest Developments
11.11 Merck & Co., Inc.
11.11.1 Merck & Co., Inc. Company Information
11.11.2 Merck & Co., Inc. Genetic Obesity Drug Product Offered
11.11.3 Merck & Co., Inc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Merck & Co., Inc. Main Business Overview
11.11.5 Merck & Co., Inc. Latest Developments
11.12 Julphar.
11.12.1 Julphar. Company Information
11.12.2 Julphar. Genetic Obesity Drug Product Offered
11.12.3 Julphar. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Julphar. Main Business Overview
11.12.5 Julphar. Latest Developments
11.13 Bristol-Myers Squibb Company.
11.13.1 Bristol-Myers Squibb Company. Company Information
11.13.2 Bristol-Myers Squibb Company. Genetic Obesity Drug Product Offered
11.13.3 Bristol-Myers Squibb Company. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Bristol-Myers Squibb Company. Main Business Overview
11.13.5 Bristol-Myers Squibb Company. Latest Developments
12 Research Findings and Conclusion
List of Tables Table 1. Genetic Obesity Drug Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions) Table 2. Major Players of Sibutramine Table 3. Major Players of Orlistat Table 4. Major Players of Sympathomimetic Drugs Table 5. Major Players of Receptors Antagonists Table 6. Major Players of Others Table 7. Genetic Obesity Drug Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions) Table 8. Global Genetic Obesity Drug Market Size by Type (2018-2023) & ($ Millions) Table 9. Global Genetic Obesity Drug Market Size Market Share by Type (2018-2023) Table 10. Genetic Obesity Drug Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions) Table 11. Global Genetic Obesity Drug Market Size by Application (2018-2023) & ($ Millions) Table 12. Global Genetic Obesity Drug Market Size Market Share by Application (2018-2023) Table 13. Global Genetic Obesity Drug Revenue by Players (2018-2023) & ($ Millions) Table 14. Global Genetic Obesity Drug Revenue Market Share by Player (2018-2023) Table 15. Genetic Obesity Drug Key Players Head office and Products Offered Table 16. Genetic Obesity Drug Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) Table 17. New Products and Potential Entrants Table 18. Mergers & Acquisitions, Expansion Table 19. Global Genetic Obesity Drug Market Size by Regions 2018-2023 & ($ Millions) Table 20. Global Genetic Obesity Drug Market Size Market Share by Regions (2018-2023) Table 21. Global Genetic Obesity Drug Revenue by Country/Region (2018-2023) & ($ millions) Table 22. Global Genetic Obesity Drug Revenue Market Share by Country/Region (2018-2023) Table 23. Americas Genetic Obesity Drug Market Size by Country (2018-2023) & ($ Millions) Table 24. Americas Genetic Obesity Drug Market Size Market Share by Country (2018-2023) Table 25. Americas Genetic Obesity Drug Market Size by Type (2018-2023) & ($ Millions) Table 26. Americas Genetic Obesity Drug Market Size Market Share by Type (2018-2023) Table 27. Americas Genetic Obesity Drug Market Size by Application (2018-2023) & ($ Millions) Table 28. Americas Genetic Obesity Drug Market Size Market Share by Application (2018-2023) Table 29. APAC Genetic Obesity Drug Market Size by Region (2018-2023) & ($ Millions) Table 30. APAC Genetic Obesity Drug Market Size Market Share by Region (2018-2023) Table 31. APAC Genetic Obesity Drug Market Size by Type (2018-2023) & ($ Millions) Table 32. APAC Genetic Obesity Drug Market Size Market Share by Type (2018-2023) Table 33. APAC Genetic Obesity Drug Market Size by Application (2018-2023) & ($ Millions) Table 34. APAC Genetic Obesity Drug Market Size Market Share by Application (2018-2023) Table 35. Europe Genetic Obesity Drug Market Size by Country (2018-2023) & ($ Millions) Table 36. Europe Genetic Obesity Drug Market Size Market Share by Country (2018-2023) Table 37. Europe Genetic Obesity Drug Market Size by Type (2018-2023) & ($ Millions) Table 38. Europe Genetic Obesity Drug Market Size Market Share by Type (2018-2023) Table 39. Europe Genetic Obesity Drug Market Size by Application (2018-2023) & ($ Millions) Table 40. Europe Genetic Obesity Drug Market Size Market Share by Application (2018-2023) Table 41. Middle East & Africa Genetic Obesity Drug Market Size by Region (2018-2023) & ($ Millions) Table 42. Middle East & Africa Genetic Obesity Drug Market Size Market Share by Region (2018-2023) Table 43. Middle East & Africa Genetic Obesity Drug Market Size by Type (2018-2023) & ($ Millions) Table 44. Middle East & Africa Genetic Obesity Drug Market Size Market Share by Type (2018-2023) Table 45. Middle East & Africa Genetic Obesity Drug Market Size by Application (2018-2023) & ($ Millions) Table 46. Middle East & Africa Genetic Obesity Drug Market Size Market Share by Application (2018-2023) Table 47. Key Market Drivers & Growth Opportunities of Genetic Obesity Drug Table 48. Key Market Challenges & Risks of Genetic Obesity Drug Table 49. Key Industry Trends of Genetic Obesity Drug Table 50. Global Genetic Obesity Drug Market Size Forecast by Regions (2024-2029) & ($ Millions) Table 51. Global Genetic Obesity Drug Market Size Market Share Forecast by Regions (2024-2029) Table 52. Global Genetic Obesity Drug Market Size Forecast by Type (2024-2029) & ($ Millions) Table 53. Global Genetic Obesity Drug Market Size Forecast by Application (2024-2029) & ($ Millions) Table 54. Pfizer, Inc. Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 55. Pfizer, Inc. Genetic Obesity Drug Product Offered Table 56. Pfizer, Inc. Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 57. Pfizer, Inc. Main Business Table 58. Pfizer, Inc. Latest Developments Table 59. Sanofi. Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 60. Sanofi. Genetic Obesity Drug Product Offered Table 61. Sanofi. Main Business Table 62. Sanofi. Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 63. Sanofi. Latest Developments Table 64. Tonghua Dongbao Pharmaceutical Co., Ltd. Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 65. Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Product Offered Table 66. Tonghua Dongbao Pharmaceutical Co., Ltd. Main Business Table 67. Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 68. Tonghua Dongbao Pharmaceutical Co., Ltd. Latest Developments Table 69. Biocon. Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 70. Biocon. Genetic Obesity Drug Product Offered Table 71. Biocon. Main Business Table 72. Biocon. Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 73. Biocon. Latest Developments Table 74. Adocia Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 75. Adocia Genetic Obesity Drug Product Offered Table 76. Adocia Main Business Table 77. Adocia Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 78. Adocia Latest Developments Table 79. GlaxoSmithKline Plc. Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 80. GlaxoSmithKline Plc. Genetic Obesity Drug Product Offered Table 81. GlaxoSmithKline Plc. Main Business Table 82. GlaxoSmithKline Plc. Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 83. GlaxoSmithKline Plc. Latest Developments Table 84. Novo Nordisk A/S. Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 85. Novo Nordisk A/S. Genetic Obesity Drug Product Offered Table 86. Novo Nordisk A/S. Main Business Table 87. Novo Nordisk A/S. Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 88. Novo Nordisk A/S. Latest Developments Table 89. Oramed Pharmaceuticals, Inc Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 90. Oramed Pharmaceuticals, Inc Genetic Obesity Drug Product Offered Table 91. Oramed Pharmaceuticals, Inc Main Business Table 92. Oramed Pharmaceuticals, Inc Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 93. Oramed Pharmaceuticals, Inc Latest Developments Table 94. Wockhardt. Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 95. Wockhardt. Genetic Obesity Drug Product Offered Table 96. Wockhardt. Main Business Table 97. Wockhardt. Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 98. Wockhardt. Latest Developments Table 99. Eli Lilly and Company. Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 100. Eli Lilly and Company. Genetic Obesity Drug Product Offered Table 101. Eli Lilly and Company. Main Business Table 102. Eli Lilly and Company. Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 103. Eli Lilly and Company. Latest Developments Table 104. Merck & Co., Inc. Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 105. Merck & Co., Inc. Genetic Obesity Drug Product Offered Table 106. Merck & Co., Inc. Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 107. Merck & Co., Inc. Main Business Table 108. Merck & Co., Inc. Latest Developments Table 109. Julphar. Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 110. Julphar. Genetic Obesity Drug Product Offered Table 111. Julphar. Main Business Table 112. Julphar. Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 113. Julphar. Latest Developments Table 114. Bristol-Myers Squibb Company. Details, Company Type, Genetic Obesity Drug Area Served and Its Competitors Table 115. Bristol-Myers Squibb Company. Genetic Obesity Drug Product Offered Table 116. Bristol-Myers Squibb Company. Main Business Table 117. Bristol-Myers Squibb Company. Genetic Obesity Drug Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 118. Bristol-Myers Squibb Company. Latest Developments List of Figures Figure 1. Genetic Obesity Drug Report Years Considered Figure 2. Research Objectives Figure 3. Research Methodology Figure 4. Research Process and Data Source Figure 5. Global Genetic Obesity Drug Market Size Growth Rate 2018-2029 ($ Millions) Figure 6. Genetic Obesity Drug Sales by Geographic Region (2018, 2022 & 2029) & ($ millions) Figure 7. Genetic Obesity Drug Sales Market Share by Country/Region (2022) Figure 8. Genetic Obesity Drug Sales Market Share by Country/Region (2018, 2022 & 2029) Figure 9. Global Genetic Obesity Drug Market Size Market Share by Type in 2022 Figure 10. Genetic Obesity Drug in Hospitals Pharmacy Figure 11. Global Genetic Obesity Drug Market: Hospitals Pharmacy (2018-2023) & ($ Millions) Figure 12. Genetic Obesity Drug in Retail Pharmacy Figure 13. Global Genetic Obesity Drug Market: Retail Pharmacy (2018-2023) & ($ Millions) Figure 14. Genetic Obesity Drug in Online Pharmacy Figure 15. Global Genetic Obesity Drug Market: Online Pharmacy (2018-2023) & ($ Millions) Figure 16. Genetic Obesity Drug in Others Figure 17. Global Genetic Obesity Drug Market: Others (2018-2023) & ($ Millions) Figure 18. Global Genetic Obesity Drug Market Size Market Share by Application in 2022 Figure 19. Global Genetic Obesity Drug Revenue Market Share by Player in 2022 Figure 20. Global Genetic Obesity Drug Market Size Market Share by Regions (2018-2023) Figure 21. Americas Genetic Obesity Drug Market Size 2018-2023 ($ Millions) Figure 22. APAC Genetic Obesity Drug Market Size 2018-2023 ($ Millions) Figure 23. Europe Genetic Obesity Drug Market Size 2018-2023 ($ Millions) Figure 24. Middle East & Africa Genetic Obesity Drug Market Size 2018-2023 ($ Millions) Figure 25. Americas Genetic Obesity Drug Value Market Share by Country in 2022 Figure 26. United States Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 27. Canada Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 28. Mexico Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 29. Brazil Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 30. APAC Genetic Obesity Drug Market Size Market Share by Region in 2022 Figure 31. APAC Genetic Obesity Drug Market Size Market Share by Type in 2022 Figure 32. APAC Genetic Obesity Drug Market Size Market Share by Application in 2022 Figure 33. China Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 34. Japan Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 35. Korea Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 36. Southeast Asia Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 37. India Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 38. Australia Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 39. Europe Genetic Obesity Drug Market Size Market Share by Country in 2022 Figure 40. Europe Genetic Obesity Drug Market Size Market Share by Type (2018-2023) Figure 41. Europe Genetic Obesity Drug Market Size Market Share by Application (2018-2023) Figure 42. Germany Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 43. France Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 44. UK Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 45. Italy Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 46. Russia Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 47. Middle East & Africa Genetic Obesity Drug Market Size Market Share by Region (2018-2023) Figure 48. Middle East & Africa Genetic Obesity Drug Market Size Market Share by Type (2018-2023) Figure 49. Middle East & Africa Genetic Obesity Drug Market Size Market Share by Application (2018-2023) Figure 50. Egypt Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 51. South Africa Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 52. Israel Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 53. Turkey Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 54. GCC Country Genetic Obesity Drug Market Size Growth 2018-2023 ($ Millions) Figure 55. Americas Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 56. APAC Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 57. Europe Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 58. Middle East & Africa Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 59. United States Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 60. Canada Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 61. Mexico Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 62. Brazil Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 63. China Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 64. Japan Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 65. Korea Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 66. Southeast Asia Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 67. India Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 68. Australia Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 69. Germany Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 70. France Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 71. UK Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 72. Italy Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 73. Russia Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 74. Spain Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 75. Egypt Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 76. South Africa Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 77. Israel Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 78. Turkey Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 79. GCC Countries Genetic Obesity Drug Market Size 2024-2029 ($ Millions) Figure 80. Global Genetic Obesity Drug Market Size Market Share Forecast by Type (2024-2029) Figure 81. Global Genetic Obesity Drug Market Size Market Share Forecast by Application (2024-2029)
